title: [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
abstract: Breast cancer is a heterogenous disease and hormonal factors are involved. Since national differences exist in the use of postmenopausal hormone therapy (HT) and other risk factors, associations between HT and breast cancer should be studied nationally. In Finland, estrogen-progestin therapy is associated with higher breast cancer risk than estrogen-only therapy. Also tibolone and levonorgestrel releasing intauterine device combined with estrogen are accompanied with an increased risk of breast cancer. Hormone therapy possibly promotes the growth of the existing undetectable cancer.
authors: HYKS:n naistenklinikka, HUS.
authors: Heli
authors: H
authors: Lyytinen
authors: Olavi
authors: O
authors: Ylikorkala
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D003271:Contraceptive Agents, Female / Q000009:adverse effects; D020847:Estrogen Receptor Modulators / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects; D016912:Levonorgestrel / Q000009:adverse effects; D008875:Middle Aged; D009652:Norpregnenes / Q000009:adverse effects; D017698:Postmenopause; D012307:Risk Factors
chemical_list: D003271:Contraceptive Agents, Female; D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; D016912:Levonorgestrel; C027385:tibolone